IL128059A - Pharmaceutical compositions for treatment and prevention of arteriosclerosis containing insulin resistance improving agents, angiotensin ii receptor antagonists and angiotensin converting enzyme inhibitors - Google Patents

Pharmaceutical compositions for treatment and prevention of arteriosclerosis containing insulin resistance improving agents, angiotensin ii receptor antagonists and angiotensin converting enzyme inhibitors

Info

Publication number
IL128059A
IL128059A IL12805997A IL12805997A IL128059A IL 128059 A IL128059 A IL 128059A IL 12805997 A IL12805997 A IL 12805997A IL 12805997 A IL12805997 A IL 12805997A IL 128059 A IL128059 A IL 128059A
Authority
IL
Israel
Prior art keywords
angiotensin
treatment
prevention
pharmaceutical compositions
receptor antagonists
Prior art date
Application number
IL12805997A
Other languages
English (en)
Other versions
IL128059A0 (en
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Priority to IL14575897A priority Critical patent/IL145758A0/xx
Publication of IL128059A0 publication Critical patent/IL128059A0/xx
Publication of IL128059A publication Critical patent/IL128059A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
IL12805997A 1996-07-15 1997-07-11 Pharmaceutical compositions for treatment and prevention of arteriosclerosis containing insulin resistance improving agents, angiotensin ii receptor antagonists and angiotensin converting enzyme inhibitors IL128059A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL14575897A IL145758A0 (en) 1996-07-15 1997-07-11 Pharmaceutical compositions for treatment and prevention of arteriosclerosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP18436896 1996-07-15
PCT/JP1997/002407 WO1998002183A1 (en) 1996-07-15 1997-07-11 Medicinal compositions

Publications (2)

Publication Number Publication Date
IL128059A0 IL128059A0 (en) 1999-11-30
IL128059A true IL128059A (en) 2003-12-10

Family

ID=16152008

Family Applications (2)

Application Number Title Priority Date Filing Date
IL12805997A IL128059A (en) 1996-07-15 1997-07-11 Pharmaceutical compositions for treatment and prevention of arteriosclerosis containing insulin resistance improving agents, angiotensin ii receptor antagonists and angiotensin converting enzyme inhibitors
IL145758A IL145758A (en) 1996-07-15 2001-10-04 Pharmaceutical preparations for the prevention and treatment of atherosclerotic diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL145758A IL145758A (en) 1996-07-15 2001-10-04 Pharmaceutical preparations for the prevention and treatment of atherosclerotic diseases

Country Status (19)

Country Link
US (1) US6610682B2 (es)
EP (2) EP1175902B1 (es)
KR (1) KR100540618B1 (es)
CN (2) CN1221259C (es)
AT (2) ATE306921T1 (es)
AU (1) AU714618B2 (es)
CA (1) CA2261040C (es)
CZ (2) CZ299162B6 (es)
DE (2) DE69731840T2 (es)
DK (2) DK1175902T3 (es)
ES (2) ES2250283T3 (es)
HK (1) HK1020260A1 (es)
HU (2) HU227399B1 (es)
IL (2) IL128059A (es)
NO (2) NO322314B1 (es)
NZ (1) NZ333723A (es)
PT (1) PT930076E (es)
RU (2) RU2220723C2 (es)
WO (1) WO1998002183A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047509A2 (en) * 1999-12-24 2001-07-05 Smithkline Beecham P.L.C. Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
MXPA02010090A (es) * 2000-04-12 2003-02-12 Novartis Ag Combinacion de al menos dos compuestos seleccionados de los grupos de un antagonista del receptor at-1 o un inhibidor ace o un inhibidor de la hmg-co-a reductasa.
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
US20040219208A1 (en) * 2001-08-03 2004-11-04 Ryu Kawamura Sustained-release medicines
DE10300111A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
EA009983B1 (ru) * 2003-01-31 2008-04-28 Дайити Санкио Компани, Лимитед Лекарственное средство для профилактики и лечения артериосклероза и гипертензии
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
EP1750862B1 (en) * 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
RU2441653C2 (ru) * 2005-05-31 2012-02-10 Милан Лэборетериз, Инк. Композиции, содержащие небиволол
WO2007001066A1 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
US8188270B2 (en) 2005-10-04 2012-05-29 Bayer Schering Pharma Aktiengesellschaft Polymorphous form of 5-chloro-N-({(5S)-2-oxo-3[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
US20090076104A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched losartan
RU2011124948A (ru) * 2008-11-19 2012-12-27 Мериал Лимитед Композиции, включающие 1-арилпиразол сам по себе или в комбинации с формамидином, для лечения паразитарных инфекций
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
CN107617107A (zh) * 2017-09-18 2018-01-23 浙江大学 一种复方血管紧张素转换酶类抗瘢痕制剂
CN107648611A (zh) * 2017-09-18 2018-02-02 浙江大学 复方血管紧张素转换酶类抗瘢痕外用制剂
CN110075304B (zh) * 2019-05-29 2020-02-11 四川大学华西医院 一种治疗骨关节炎的药物组合物及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231080A (en) 1985-10-15 1993-07-27 Hoechst Aktiengesellschaft Method for the treatment of atherosclerosis, thrombosis, and peripheral vessel disease
DE3536687A1 (de) * 1985-10-15 1987-04-16 Hoechst Ag Verfahren zur behandlung von atherosklerose, thrombose und der peripheren gefaesskrankheit
US5223522A (en) * 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
WO1989008651A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
CA2016467A1 (en) * 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
DE3925759A1 (de) * 1989-08-03 1991-02-07 Thera Patent Verwaltungs Gmbh Verwendung von ace-inhibitoren fuer die atheroskleroseprophylaxe
US5061694A (en) * 1989-10-23 1991-10-29 E. R. Squibb & Sons, Inc. Method for stabilizing or causing regression of atherosclerosis in coronary arteries employing an ace inhibitor
CA2026686A1 (en) 1989-10-30 1991-05-01 Werner Tschollar Method for preventing onset of type ii diabetes employing an ace inhibitor
GB2241890A (en) 1990-03-12 1991-09-18 Squibb & Sons Inc Preventing onset of or treating protein catabolism using an ace inhibitor
US5298497A (en) 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
IS1756B (is) * 1991-02-21 2000-12-28 Sankyo Company Limited Hliðstæðuaðferð til framleiðslu 1-Biphenylmethylimidazole afleiða
US5616599A (en) 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
CA2118706A1 (en) * 1992-07-13 1994-01-20 Saizo Shibata Novel thiazolidinedione compounds and use thereof
JPH0741423A (ja) 1993-02-24 1995-02-10 Sankyo Co Ltd 動脈硬化症治療剤
AU6114794A (en) * 1993-02-24 1994-09-14 Sankyo Company Limited Arteriosclerosis remedy
NO303782B1 (no) * 1994-03-23 1998-08-31 Sankyo Co Tiazolidin- og oksazolidinderivater og farmas°ytiske preparater inneholdende slike, samt deres anvendelse til fremstilling av medikamenter
CA2186606A1 (en) * 1994-03-29 1995-10-05 Edward B. Nelson Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
CN1215338A (zh) 1996-04-05 1999-04-28 武田药品工业株式会社 包含具有血管紧张素ⅱ拮抗活性的化合物的药物组合物

Also Published As

Publication number Publication date
HU227399B1 (en) 2011-05-30
CZ10299A3 (cs) 1999-06-16
CZ299162B6 (cs) 2008-05-07
PT930076E (pt) 2005-01-31
EP1175902A1 (en) 2002-01-30
NO990166D0 (no) 1999-01-14
RU2220723C2 (ru) 2004-01-10
EP0930076A4 (en) 2001-10-04
KR20000023757A (ko) 2000-04-25
ES2250283T3 (es) 2006-04-16
ES2232873T3 (es) 2005-06-01
NO20056021L (no) 1999-03-15
EP0930076B1 (en) 2004-12-01
CN1230122A (zh) 1999-09-29
HUP9903166A3 (en) 2003-09-29
CN1476833A (zh) 2004-02-25
US6610682B2 (en) 2003-08-26
HU225415B1 (en) 2006-11-28
AU3459597A (en) 1998-02-09
ATE306921T1 (de) 2005-11-15
HK1020260A1 (en) 2000-04-07
US20020013308A1 (en) 2002-01-31
EP1175902B1 (en) 2005-10-19
ATE283704T1 (de) 2004-12-15
IL145758A (en) 2006-06-11
EP0930076A1 (en) 1999-07-21
HUP0600501A3 (en) 2008-10-28
DE69734405T2 (de) 2006-08-03
CA2261040C (en) 2009-01-20
IL128059A0 (en) 1999-11-30
HU0600501D0 (en) 2006-08-28
CN1221259C (zh) 2005-10-05
DE69731840T2 (de) 2005-08-04
DK1175902T3 (da) 2005-12-19
KR100540618B1 (ko) 2006-01-12
DE69734405D1 (de) 2006-03-02
NO322314B1 (no) 2006-09-11
RU2183128C2 (ru) 2002-06-10
CZ300089B6 (cs) 2009-01-28
WO1998002183A1 (en) 1998-01-22
NZ333723A (en) 2000-09-29
DE69731840D1 (de) 2005-01-05
CN1155409C (zh) 2004-06-30
HUP9903166A2 (hu) 2000-09-28
NO334217B1 (no) 2014-01-13
NO990166L (no) 1999-03-15
AU714618B2 (en) 2000-01-06
CA2261040A1 (en) 1998-01-22
DK0930076T3 (da) 2005-01-31

Similar Documents

Publication Publication Date Title
IL128059A (en) Pharmaceutical compositions for treatment and prevention of arteriosclerosis containing insulin resistance improving agents, angiotensin ii receptor antagonists and angiotensin converting enzyme inhibitors
IL115059A (en) Pharmaceutical composition for oral administration comprising a combination of ramipril and a dihydropyridine compound
CA2251331A1 (en) Calcilytic compounds
RU2001126527A (ru) Средство и способ лечения или профилактики артериосклероза
WO2001001972A3 (en) SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
FR2739553B1 (fr) Utilisation d'antagonistes de la bradykinine pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute
ZA981779B (en) The use of levobupivacaine in facial surgery
EP1057472A4 (en) SOLID PREPARATION FOR ORAL HYGIENE
NZ326345A (en) Composition containing diosgenin
GR3030954T3 (en) Children-proof package for active substance-containing plaster
EE03385B1 (et) Angiotensiini II tüüp 1 retseptori antagonistide kasutamine düspeptiliste sümptomite profülaktikas ja/või ravis kasutatava ravimi valmistamiseks ja angiotensiini II tüüp 1 retseptori antagoniste sisaldavad ravimpreparaadid
CA2269031A1 (en) Treatment of urinary incontinence and compositions for use therein
CA2551963A1 (en) Pharmaceutical compositions and treatment of arteriosclerosis with cs-866
AU7937794A (en) Use of lithium compounds for treating high blood pressure
HUP9903818A2 (hu) Transzdermális terápiás rendszer ösztriolt tartalmazó hatóanyag-kombinációval

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired